November 18, 2026
Health news, explained with evidence
LIVE

White House Withdraws Nomination of Heidi Overton to Lead FDA

🧠 AI Analysis 2 min read 👁 5

The White House has pulled the nomination of Heidi Overton, MD, PhD, for FDA commissioner after it became clear she lacked the necessary votes in the Senate.

White House Withdraws Nomination of Heidi Overton to Lead FDA🧠AI Analysis

Photo: medpagetoday.com

Key points

  • White House withdraws Heidi Overton's nomination for FDA commissioner
  • Nominee faced bipartisan scrutiny over childhood vaccine views and scientific independence
  • Senate Health Committee Chairman Bill Cassidy withheld crucial support

The administration announced on Tuesday that it has rescinded the nomination of Heidi Overton, MD, PhD, to head the Food and Drug Administration. Overton, a physician and White House domestic policy advisor, was originally nominated in August to bring stability to the agency following a turbulent tenure under the previous commissioner, Marty Makary, MD, MPH. Her path to confirmation stalled as she faced bipartisan skepticism regarding her stance on childhood immunizations and her willingness to maintain scientific independence from political figures.

During a September hearing, Senate Health Committee Chairman Bill Cassidy, MD (R-La.) questioned Overton extensively about her commitment to established vaccine standards, previously describing her support for separating combination shots like the measles, mumps, and rubella vaccine as nearly disqualifying. To secure a favorable committee vote, Overton needed unanimous support from all 12 Republican members alongside the 11 Democratic seats, a threshold she could not reach. Republican lawmakers are currently working to clear pending nominees before control of the Senate shifts in January.

What to know: Opposition to the nomination also arose from figures within the Make America Healthy Again movement, who criticized administration policies related to pesticide litigation. The FDA remains under the acting leadership of Kyle Diamantas while the agency continues to navigate internal departures and restructuring following significant staff reductions. Readers should consult qualified healthcare professionals for medical guidance.

Source medpagetoday.com — medpagetoday.com/washington-watch/fdageneral/123940 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.